Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials

IMPORTANCE: The prognostic impact of DNA mismatch repair (MMR) status in stage III colon cancer patients receiving FOLFOX (folinic acid, fluorouracil, and oxaliplatin) adjuvant chemotherapy remains controversial. OBJECTIVE: To determine the association of MMR status with disease-free survival (DFS)...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:JAMA Oncol
Glavni autori: Zaanan, Aziz, Shi, Qian, Taieb, Julien, Alberts, Steven R., Meyers, Jeffrey P., Smyrk, Thomas C., Julie, Catherine, Zawadi, Ayman, Tabernero, Josep, Mini, Enrico, Goldberg, Richard M., Folprecht, Gunnar, Van Laethem, Jean Luc, Le Malicot, Karine, Sargent, Daniel J., Laurent-Puig, Pierre, Sinicrope, Frank A.
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2017
Teme:
Brief Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5784452/
https://ncbi.nlm.nih.gov/pubmed/28983557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.2899
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items